ArticleNature2024
Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed.
- Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer.Science advances · 2026Article
- SPTLC2-driven sphingolipid reprogramming of neutrophils impairs anti-tumour immunity and drives liver cancer progression.Oncogene · 2026Article
- Inhibition of the lipocalin-2-phosphatidylserine axis restores natural killer cell immune surveillance.Cell reports. Medicine · 2026Article
- The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Ceramide signaling in non-small-cell lung cancer: from dysregulation to targeted therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- A Microbial Lipid-ATP Synthase Axis Fuels NK Cell Antitumor Activity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Immune implications and therapeutic opportunities of tumor glycosylation.Nature cancer · 2026Review
- Targeting DGAT1 reprograms lipid landscape and restores CD8⁺ T cell immunity in pancreatic cancer.Nature communications · 2026Article
- Molecular regulation and physiological role of GOLPH3-mediated Golgi retention.Nature communications · 2026Article
- Inhibition of glycosphingolipid synthesis overcomes the steric hindrance of CD30 N-glycans to augment CD30-targeted immunotherapeutic efficacy.Cellular & molecular immunology · 2026Article
- The metabolic plasticity of cancer stem cells: bidirectional crosstalk with organ-resident cells.Experimental & molecular medicine · 2026Review
- Metabolites as signalling molecules in the tumour immune microenvironment.Nature reviews. Immunology · 2026Review
- Integrative proteomic characterization of human lung adenocarcinoma with KRAS G12 mutations reveals molecular pathogenesis.Journal of advanced research · 2026Article
- BCAT1 inhibits crotonate-related epigenetic modulation of metabolic genes in tumor-associated macrophages to counter immunosuppression.Nature communications · 2026Article
- Metabolic Salvage and Acyl-chain Remodeling Support Glycosphingolipid Synthesis within the PDAC Tumor Microenvironment.bioRxiv : the preprint server for biology · 2026Article
- SAICAR Drives T Regulatory Cell Differentiation and FOXP3 Maintenance to Promote Immunotherapy Resistance.Cancer research · 2026Article
- Vitamin D remodels the tumor microenvironment to suppress gastric cancer progression through cancer-associated fibroblasts-secreted exosomal miR-378c targeting KDSR.Archives of pharmacal research · 2026Article
- SLC33A1 exports oxidized glutathione to maintain endoplasmic reticulum redox homeostasis.Nature cell biology · 2026Article
- A macrophage MHC-I axis links intratumoral heterogeneity to terminal CD8NPJ precision oncology · 2026Article
- TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation.Oncogene · 2026Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Mariluz SoulaLaboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-1637-0802
Gokhan UnluLaboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-2704-2724
Rachel WelchLaboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA.
Aleksey ChudnovskiyLaboratory of Lymphocyte Dynamics, The Rockefeller University, New York, NY, USA.
Beste UygurLaboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-0528-9099
Vyom ShahCold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA.ORCID 0000-0001-6874-5285
Hanan AlwaseemThe Proteomics Resource Center, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-4946-1436
Paul BunkCold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA.
Vishvak SubramanyamDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.
Hsi-Wen YehLaboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA.
Artem KhanLaboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-1240-8674
Søren HeisselThe Proteomics Resource Center, The Rockefeller University, New York, NY, USA.ORCID 0000-0003-2692-5602
Hani GoodarziDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9648-8949
Gabriel D VictoraLaboratory of Lymphocyte Dynamics, The Rockefeller University, New York, NY, USA.ORCID 0000-0001-8807-348X
Semir BeyazCold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA.ORCID 0000-0003-4730-4012
Kıvanç BirsoyLaboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, NY, USA. kbirsoy@rockefeller.edu.ORCID 0000-0002-7579-9895
Funding
Single-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI John Edward Moses · 1987 to 2026
$118.9MSingle-Cell & Computational Biology CoreU54CA261701 · NCI · ROCKEFELLER UNIVERSITY · PI Sohail F. Tavazoie · 2021 to 2026
$9.1MIdentification of metabolic regulators of glycerolipid synthesis and storageR01DK123323 · NIDDK · ROCKEFELLER UNIVERSITY · PI BIRSOY, KIVANC · 2019 to 2023
$2.5MNCI NIH HHS P30 CA045508NCI NIH HHS U54 CA261701NIDDK NIH HHS R01 DK123323
Abstract
Cancer cells frequently alter their lipids to grow and adapt to their environment
Indexed as
GlycosphingolipidsImmune EvasionNeoplasmsProto-Oncogene Proteins p21(ras)Tumor EscapeAnimalsCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationFemaleImmune Checkpoint InhibitorsInterferon-gammaInterferon gamma ReceptorKiller Cells, NaturalLipidomicsMiceGlycosphingolipidsHras protein, mouseIfngr1 protein, mouseImmune Checkpoint InhibitorsInterferon-gammaInterferon gamma ReceptorProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.